Montpellier-based SeqOne, a deeptech company specializing in AI-powered genomic analysis, has announced a €20 million oversubscribed growth funding round led by Supernova Invest, with continued backing from Elaia, Omnes, and Mérieux Equity Partners. The new capital will support SeqOne’s international expansion, U.S. market entry, and platform development as demand for automated, scalable NGS data interpretation accelerates.
CEO Martin Dubuc said the investment reflects confidence in the company’s mission to deliver precision medicine globally. He noted the funds will help scale operations, enhance AI capabilities, and solidify SeqOne’s position as a trusted partner for molecular labs worldwide. The company currently supports 140 labs in 22 countries and expects to process over 110,000 patient analyses in 2025.
